Prognostic factors and antibiotics in Vibrio vulnificus septicemia.

Abstract

BACKGROUND:

Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular.

METHODS:

Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those without [corrected] HBNCLs (group 1) [corrected] and those with [corrected] HBNCLs (group 2) [corrected]Patients were further divided into subgoups with [corrected] fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup).

RESULTS:

A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P = .006) and a higher proportion of shock at arrival at the medical center (P = .015) than the nonfatal subgroup. In group 2, the effect of a first- or second-generation cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P<.001); significant differences were found between the fatal and nonfatal subgroups in the APACHE II score (P<.001), number who were in shock at arrival at the medical center (P = .02), delayed surgical intervention (P = .03), and peripheral leukocytosis (P = .03). Shock at arrival at the medical center (odds ratio [OR], 19.25; 95% confidence interval [CI], 1.768-209.54; P = .02) was an independent risk factor for fatality in patients without HBNCLs. Use of a third-generation cephalosporin and tetracycline or its analogue significantly reduced fatality rates in patients with HBNCLs (OR, 0.037; 95% CI, 0.007-0.192; P<.001).

CONCLUSION:

Septic shock is a determinant of fatality in patients with V vulnificus septicemia without HBNCLs; our data suggest that the combination of a third-generation cephalosporin and tetracycline or its analogue may be a better choice in antimicrobial treatment of V vulnificus septicemic patients with HBNCLs.

• Authors: Jien-Wei Liu, Ing-Kit Lee, Hung-Jen Tang, Wen-Chien Ko, Hsin-Chun Lee, Yung-Ching Liu, Po-Ren Hsueh, Yin-Ching Chuang
• Journal: Archives of internal medicine (Arch Intern Med) Vol. 166 Issue 19 Pg. 2117-23 (Oct 23 2006) ISSN: 0003-9926 [Print] United States
• PMID: 17060542 (Publication Type: Comparative Study, Journal Article, Multicenter Study)

Chemical References

• Anti-Bacterial Agents

Topics

• APACHE
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Bacteremia (drug therapy, microbiology)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Microbial Sensitivity Tests
• Middle Aged
• Multivariate Analysis
• Prognosis
• Retrospective Studies
• Risk Factors
• Taiwan (epidemiology)
• Treatment Outcome
• Vibrio Infections (drug therapy, microbiology)
• Vibrio vulnificus (isolation & purification)